At NewBridge Partners we're really a growth-stock investor. In a biotechnology company, that's very difficult to find, outside of the large-cap names. But that's not to say that we're not looking for companies that will be turning a profit shortly. Often, that's where the uncovered gems lie.
Genomics actually seems to be a theme of the conference.
You know, you don't want to fight city hall when investing. Many times people will use money flow. And that may be an opportunity for investment, because others are investing there. Well, when you come to a conference, you can kind of gauge the interest, the success of the company, by the attendance in the room. And when you go to many of the genomic presentations here, you see that there's standing room only in a lot of those presentations, so apparently there's a tremendous amount of interest.